ATE535239T1 - Formulierungen enthaltend amiodaron und sulfoalkylethercyclodextrin - Google Patents
Formulierungen enthaltend amiodaron und sulfoalkylethercyclodextrinInfo
- Publication number
- ATE535239T1 ATE535239T1 AT03728598T AT03728598T ATE535239T1 AT E535239 T1 ATE535239 T1 AT E535239T1 AT 03728598 T AT03728598 T AT 03728598T AT 03728598 T AT03728598 T AT 03728598T AT E535239 T1 ATE535239 T1 AT E535239T1
- Authority
- AT
- Austria
- Prior art keywords
- ethercyclodextrin
- amiodaron
- sulfoalkyl
- formulations containing
- formulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000020446 Cardiac disease Diseases 0.000 abstract 1
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 abstract 1
- 229960005260 amiodarone Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Medical Informatics (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/139,620 US6869939B2 (en) | 2002-05-04 | 2002-05-04 | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
PCT/US2003/013250 WO2003092590A2 (en) | 2002-05-04 | 2003-04-29 | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE535239T1 true ATE535239T1 (de) | 2011-12-15 |
Family
ID=29399340
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03728598T ATE535239T1 (de) | 2002-05-04 | 2003-04-29 | Formulierungen enthaltend amiodaron und sulfoalkylethercyclodextrin |
Country Status (16)
Country | Link |
---|---|
US (1) | US6869939B2 (de) |
EP (2) | EP1501496B1 (de) |
JP (2) | JP4764004B2 (de) |
KR (1) | KR100984197B1 (de) |
AT (1) | ATE535239T1 (de) |
AU (1) | AU2003234285B2 (de) |
CA (1) | CA2483774C (de) |
CY (1) | CY1112527T1 (de) |
DK (2) | DK2402008T3 (de) |
ES (2) | ES2567716T3 (de) |
HU (1) | HUE027551T2 (de) |
IL (2) | IL165022A0 (de) |
MX (1) | MXPA04010925A (de) |
PT (1) | PT1501496E (de) |
SI (2) | SI1501496T1 (de) |
WO (1) | WO2003092590A2 (de) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1713504B1 (de) | 2004-01-30 | 2017-06-07 | Zoetis Services LLC | Antimikrobielle konservierungsmittel für mehrdosis-formulierungen unter verwendung von beta-cyclodextrinen für flüssige dosierformen |
WO2005104712A2 (en) | 2004-04-23 | 2005-11-10 | Cydex, Inc. | Dpi formulation containing sulfoalkyl ether cyclodextrin |
US8092559B2 (en) | 2004-05-12 | 2012-01-10 | Luca Technologies, Inc. | Generation of hydrogen from hydrocarbon bearing materials |
US7426960B2 (en) | 2005-05-03 | 2008-09-23 | Luca Technologies, Inc. | Biogenic fuel gas generation in geologic hydrocarbon deposits |
US20100204178A1 (en) | 2006-10-02 | 2010-08-12 | James Cloyd | Novel parenteral carbamazepine formulation |
US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
US7416879B2 (en) * | 2006-01-11 | 2008-08-26 | Luca Technologies, Inc. | Thermacetogenium phaeum consortium for the production of materials with enhanced hydrogen content |
AU2007230716B2 (en) | 2006-03-28 | 2012-05-03 | Javelin Pharmaceuticals, Inc. | Formulations of low dose diclofenac and beta-cyclodextrin |
MX2008012496A (es) | 2006-03-28 | 2009-01-07 | Javelin Pharmaceuticals Inc | Formulaciones de farmacos anti-inflamatorios no esteroidales de baja dosis y beta-ciclodextrina. |
US7696132B2 (en) | 2006-04-05 | 2010-04-13 | Luca Technologies, Inc. | Chemical amendments for the stimulation of biogenic gas generation in deposits of carbonaceous material |
US7977282B2 (en) | 2006-04-05 | 2011-07-12 | Luca Technologies, Inc. | Chemical amendments for the stimulation of biogenic gas generation in deposits of carbonaceous material |
WO2008034040A1 (en) * | 2006-09-15 | 2008-03-20 | Regents Of The University Of Minnesota | Topiramate compositions and methods for their use |
US20090239942A1 (en) | 2006-09-15 | 2009-09-24 | Cloyd James C | Topiramate Compositions and Methods of Making and Using the Same |
US20090270496A1 (en) * | 2007-05-03 | 2009-10-29 | Courchesne William E | Antifungal compounds |
US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
US8479813B2 (en) | 2009-12-16 | 2013-07-09 | Luca Technologies, Inc. | Biogenic fuel gas generation in geologic hydrocarbon deposits |
EP2335686A1 (de) | 2009-12-21 | 2011-06-22 | LEK Pharmaceuticals d.d. | Wässrige intravenöse Nanosuspension mit minimalen Nebenwirkungen |
NL2004260C2 (en) * | 2010-02-18 | 2011-08-22 | Univ Amsterdam | Disinfectant composition and its use in dental treatment. |
AU2011264919A1 (en) | 2010-06-11 | 2013-01-10 | Baxter Healthcare S.A. | Formulations including amiodarone and salts thereof and methods of their manufacture and use |
US20140221490A1 (en) | 2011-07-20 | 2014-08-07 | Hospira, Inc. | Methods of treating pain |
EP3446692A1 (de) | 2011-11-29 | 2019-02-27 | Jurox Pty. Ltd. | Verfahren zur konservierung injizierbarer pharmazeutischer zusammensetzungen mit einem cyclodextrin und einem hydrophoben wirkstoff |
WO2013116366A1 (en) * | 2012-01-30 | 2013-08-08 | Baxter International Inc. | Non-anticoagulant sulfated or sulfonated polysaccharides |
DK2814849T3 (da) | 2012-02-15 | 2020-03-09 | Cydex Pharmaceuticals Inc | Fremgangsmåde til fremstilling af cyclodextrin-derivater |
AU2013226073B2 (en) | 2012-02-28 | 2016-05-05 | Cydex Pharmaceuticals, Inc. | Alkylated cyclodextrin compositions and processes for preparing and using the same |
US9004162B2 (en) | 2012-03-23 | 2015-04-14 | Transworld Technologies Inc. | Methods of stimulating acetoclastic methanogenesis in subterranean deposits of carbonaceous material |
WO2014060548A1 (de) * | 2012-10-17 | 2014-04-24 | Sapiotec Gmbh | Anthocyanidin-komplex zur behandlung von multiplem myelom |
CA2888822C (en) | 2012-10-22 | 2021-01-26 | Cydex Pharmaceuticals, Inc. | Alkylated cyclodextrin compositions and processes for preparing and using the same |
DK2919791T3 (da) * | 2012-11-15 | 2017-07-17 | Sapiotec Gmbh | Delphinidin-kompleks som antiflogistisk eller immunsuppressivt aktivt stof |
EP2773033B1 (de) | 2013-02-28 | 2018-12-05 | Dialog Semiconductor GmbH | Ladungspumpenverfahren mit VDD/2 und VDD/3 |
GB201312737D0 (en) | 2013-07-17 | 2013-08-28 | Univ Greenwich | Cyclodextrin |
JP6914188B2 (ja) | 2014-08-22 | 2021-08-04 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | 分画アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法 |
US10736891B2 (en) * | 2016-01-07 | 2020-08-11 | Roy MADIGAN | Composition and method for treating chagas disease |
WO2017149552A1 (en) * | 2016-03-04 | 2017-09-08 | Sun Pharmaceutical Industries Ltd. | Parenteral dosage form of amiodarone |
CN107753439A (zh) * | 2016-08-22 | 2018-03-06 | 黑龙江迪龙制药有限公司 | 一种注射用盐酸胺碘酮及其制备方法 |
EP3541364A1 (de) | 2016-11-18 | 2019-09-25 | AiCuris Anti-infective Cures GmbH | Neuartige formulierungen von amidinsubstituierten beta-lactam-verbindungen auf basis von modifizierten cyclodextrinen und ansäuerungsmitteln, deren herstellung und verwendung als antimikrobielle pharmazeutische zusammensetzungen |
EP3968979A4 (de) * | 2019-05-15 | 2023-03-01 | Bexson Biomedical, Inc. | Ketaminformulierung für subkutane injektion |
US20230000997A1 (en) | 2019-08-06 | 2023-01-05 | L.E.A.F. Holdings Group Llc | Processes of preparing polyglutamated antifolates and uses of their compositions |
CN115969833A (zh) * | 2023-01-03 | 2023-04-18 | 上海上药第一生化药业有限公司 | 胺碘酮药物组合物、注射液及其制备方法及含其的注射器 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0491812A4 (en) | 1989-09-14 | 1992-11-04 | Australian Commercial Research & Development Limited | Drug delivery compositions |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
EP0518930A4 (en) | 1990-03-02 | 1993-09-15 | Australian Commercial Research & Development Limited | Cyclodextrin compositions and methods for pharmaceutical and industrial applications |
US5234949A (en) | 1992-04-01 | 1993-08-10 | Academic Pharmaceuticals, Inc. | Parenteral solutions containing amiodarone in acetate buffer solution |
FR2735978B1 (fr) * | 1995-06-30 | 1997-09-19 | Sanofi Sa | Composition pharmaceutique d'amiodarone pour administration parenterale |
UA57734C2 (uk) * | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Комплекси включення арилгетероциклічних солей |
US5916883A (en) | 1996-11-01 | 1999-06-29 | Poly-Med, Inc. | Acylated cyclodextrin derivatives |
US5874418A (en) * | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
EE200100382A (et) | 1999-01-21 | 2002-12-16 | Bristol-Myers Squibb Company | Ras-farnesüültransferaasi inhibiitori ja sulfobutüüleeter-7-ß-tsüklodekstriini või 2-hüdroksüpropüül-ß-tsüklodekstriini kompleks ja selle valmistamise meetod |
US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
GB9921958D0 (en) * | 1999-09-16 | 1999-11-17 | Pharmacia & Upjohn Spa | Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins |
US6479541B1 (en) * | 2000-03-30 | 2002-11-12 | Baxter International | Amiodarone-containing parenteral administration |
-
2002
- 2002-05-04 US US10/139,620 patent/US6869939B2/en not_active Expired - Lifetime
-
2003
- 2003-04-29 DK DK11182697.0T patent/DK2402008T3/en active
- 2003-04-29 PT PT03728598T patent/PT1501496E/pt unknown
- 2003-04-29 AU AU2003234285A patent/AU2003234285B2/en not_active Expired
- 2003-04-29 ES ES11182697.0T patent/ES2567716T3/es not_active Expired - Lifetime
- 2003-04-29 WO PCT/US2003/013250 patent/WO2003092590A2/en active Application Filing
- 2003-04-29 ES ES03728598T patent/ES2378306T3/es not_active Expired - Lifetime
- 2003-04-29 IL IL16502203A patent/IL165022A0/xx unknown
- 2003-04-29 EP EP03728598A patent/EP1501496B1/de not_active Expired - Lifetime
- 2003-04-29 CA CA2483774A patent/CA2483774C/en not_active Expired - Lifetime
- 2003-04-29 SI SI200332113T patent/SI1501496T1/sl unknown
- 2003-04-29 SI SI200332474A patent/SI2402008T1/sl unknown
- 2003-04-29 HU HUE11182697A patent/HUE027551T2/en unknown
- 2003-04-29 JP JP2004500775A patent/JP4764004B2/ja not_active Expired - Lifetime
- 2003-04-29 DK DK03728598.8T patent/DK1501496T3/da active
- 2003-04-29 AT AT03728598T patent/ATE535239T1/de active
- 2003-04-29 EP EP11182697.0A patent/EP2402008B1/de not_active Expired - Lifetime
- 2003-04-29 KR KR1020047017639A patent/KR100984197B1/ko active IP Right Grant
- 2003-04-29 MX MXPA04010925A patent/MXPA04010925A/es active IP Right Grant
-
2004
- 2004-11-04 IL IL165022A patent/IL165022A/en active IP Right Grant
-
2011
- 2011-03-07 JP JP2011048873A patent/JP5656692B2/ja not_active Expired - Lifetime
-
2012
- 2012-02-23 CY CY20121100190T patent/CY1112527T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP2402008A1 (de) | 2012-01-04 |
HUE027551T2 (en) | 2016-10-28 |
AU2003234285B2 (en) | 2007-01-04 |
JP2011116776A (ja) | 2011-06-16 |
WO2003092590A2 (en) | 2003-11-13 |
ES2378306T3 (es) | 2012-04-11 |
KR100984197B1 (ko) | 2010-09-28 |
MXPA04010925A (es) | 2005-02-14 |
EP1501496A2 (de) | 2005-02-02 |
DK2402008T3 (en) | 2016-05-02 |
AU2003234285A1 (en) | 2003-11-17 |
CA2483774A1 (en) | 2003-11-13 |
PT1501496E (pt) | 2012-02-20 |
CY1112527T1 (el) | 2015-12-09 |
ES2567716T3 (es) | 2016-04-26 |
WO2003092590A3 (en) | 2004-01-22 |
EP2402008B1 (de) | 2016-01-27 |
US20030216353A1 (en) | 2003-11-20 |
EP1501496A4 (de) | 2006-05-31 |
US6869939B2 (en) | 2005-03-22 |
IL165022A0 (en) | 2005-12-18 |
EP1501496B1 (de) | 2011-11-30 |
CA2483774C (en) | 2011-07-19 |
KR20040106452A (ko) | 2004-12-17 |
IL165022A (en) | 2011-08-31 |
SI2402008T1 (sl) | 2016-05-31 |
JP4764004B2 (ja) | 2011-08-31 |
JP2005530744A (ja) | 2005-10-13 |
SI1501496T1 (sl) | 2012-04-30 |
DK1501496T3 (da) | 2012-03-19 |
JP5656692B2 (ja) | 2015-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE535239T1 (de) | Formulierungen enthaltend amiodaron und sulfoalkylethercyclodextrin | |
ATE455092T1 (de) | Substituierte tetracyclin-verbindungen zur behandlung von malaria | |
DE10085007T1 (de) | Antiinfektionszusammensetzungen zur Behandlung von erkranktem Gewebe, wie Lippenherpes | |
ATE322258T1 (de) | Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren | |
ECSP066311A (es) | Derivados de la piperazina y su uso como agentes terapéuticos | |
NO20034122D0 (no) | Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte | |
NO20053077D0 (no) | Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer. | |
NO20055098D0 (no) | Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser | |
ATE508114T1 (de) | Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung | |
ATE288747T1 (de) | Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren | |
DE602004012440D1 (de) | Sprühbare zusammensetzung zur verabreichung von vitamin d derivaten | |
NO20041386L (no) | Kombinasjoner for bahandling av immunoinflammatoriske forstyrrelser | |
DK1614419T3 (da) | Midler til forebyggelse/behandling af retinale nervesygdomme, indeholdende alkyletherderivater eller salte deraf | |
AU2003260436A1 (en) | Pyrimidine compounds | |
SE0102147D0 (sv) | New methods | |
DE29901517U1 (de) | Vorrichtung zur abtragenden Behandlung von Hornhaut, insbesondere bei der Fußpflege | |
BRPI0511125A (pt) | usos de ácido 5,6,7-triidroxieptanóico seus e análogos | |
DE50114605D1 (de) | No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz | |
EP1248792A4 (de) | Antisens-modulierung der expression des peroxisomproliferator aktivierten rezeptors gamma | |
SE0002729D0 (sv) | Novel compound form | |
DE60213234D1 (de) | 4-(penylpiperidin-4-ylidenmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen, angstzuständen oder erkrankungen des magen-darm-trakts | |
WO2004098522A3 (en) | Gemini vitamin d3 compounds and methods of use thereof | |
NO20060655L (no) | 2-alkyliden-19-Nor-vitamin D derivater for behandling av osteofeni eller osteoporose hos hannkjonn | |
HK1065305A1 (en) | Substituted 4-aminocyclohexanol derivatives | |
DE60228988D1 (de) | Monohyroxycarbamezepin zur verwendung bei der herstellung eines medikaments zur behandlung von affektiver psychose, aufmerksamkeits störungen und neuropathischen schmerzen |